VIP
Educational resource. Not medical advice. No dosing or instructions.
Safety grade
5/10
Moderate
Also known as
vasoactive intestinal peptidevasoactive intestinal polypeptidevip peptidevip
AA sequence
Not available yet.
What it is
VIP is a bioactive compound discussed in research and/or clinical contexts. This entry summarizes what it is, what it is studied for, and key evidence limitations without providing protocols.
Why people are interested in this peptide and how it is commonly discussed in real-world wellness, rehabilitation, and athletic communities.
Why people are interested
- a bioactive compound discussed in research and/or clinical contexts
- this entry summarizes what it is, what it is studied for, and key evidence limitations without providing protocols
- general recovery and resilience interest (anecdotal)
- common biohacker curiosity due to community reports
- interest in mechanisms suggested by early evidence
- used in goal-based stacking discussions (anecdotal)
- exploration in wellness communities despite evidence limits
VIP (vasoactive intestinal peptide) is a potent neuropeptide affecting blood vessels, lungs, and gut function. It is not a routine wellness peptide; altering these systems outside medical oversight can be risky.
Common reasons people consider it
- research relevance in airway, vascular, and GI signaling
- physiology relevance in smooth muscle relaxation and secretion pathways
- often discussed for inflammatory or respiratory themes (claims can be speculative)
Most commonly reported downsides
- flushing
- headache
- lightheadedness
- nausea or diarrhea
Rare but important symptoms to watch for
These are uncommon, but if they occur, stop and seek medical care.
- fainting or collapse from blood pressure effects
- severe shortness of breath or wheezing
- severe allergic reaction symptoms (hives, facial swelling, trouble breathing)
Who should be cautious
- people with low blood pressure or on vasodilators/blood pressure meds
- people with significant asthma/airway reactivity or severe GI disease
- pregnant or breastfeeding individuals
- adolescents (high consequence plus inappropriate for non-clinical use)
Interactions summarize known or plausible ways this peptide may intersect with medications, supplements, or physiologic states. Use this as a risk-awareness map: what to ask about, what to watch for, and what deserves a clinician conversation.
Medication classes
Supplement classes
None
Other peptides
None
Developmental risk is flagged due to limited adolescent data and uncertain long-term effects. Endocrine, growth, neurodevelopmental, and metabolic setpoints may be sensitive to perturbation. This section is descriptive only; uncertainty is explicitly acknowledged.
No curated human clinical sources have been added yet.
Status reflects how VIP appears in clinical literature and/or real-world contexts. This is descriptive only. Classification describes what VIP is and the general domain where it appears.
Pep-Talk is informational only and not medical advice. We make no warranties and are not liable for actions you take. You are responsible for your decisions and outcomes.
Community notes
Educational discussion only. No dosing, protocols, schedules, or instructions. Submissions are moderated before appearing.
Loading…
Submit a note